Get started
Author

Sufia Safina

Observed names: S Z Safina, S. Safina, S. Z. Safina, S.Z. Safina, S.  Z. Safina, Sufia Z Safina, Sufia Zievna Safina, Sufiia Safina, Sufiia Z Safina, С З Сафина, С. З. Сафина
ORCID: 0000-0002-5309-8406
Observed ORCID: 0000-0002-5309-8406
OpenAlex ID: A5016059034
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
2023 · Shannon N. Westin, Kathleen Moore, et al. · Journal of Clinical Oncology · 430
PDF
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
2021 · Salma K. Jabbour, Ki Hyeong Lee, et al. · JAMA Oncology · 288
PDF
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
2024 · Fred Saad, Egils Vjaters, et al. · Journal of Clinical Oncology · 199
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
2017 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet · 175
PDF
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
2019 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet Oncology · 93
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 83
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
2012 · Massimo Cristofanilli, Stephen R. D. Johnston, et al. · Breast Cancer Research and Treatment · 72
PDF
KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.
2019 · Ravindra Uppaluri, Nancy Y. Lee, et al. · Journal of Clinical Oncology · 52
Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study
2019 · Natalia Dengina, Timur Mitin, et al. · ESMO Open · 51
Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry
2017 · Ilya Tsimafeyeu, Tatiana Zolotareva, et al. · Clinical Genitourinary Cancer · 34
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
2022 · Martin Reck, Ki Hyeong Lee, et al. · Journal of Clinical Oncology · 33
Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study
2025 · Ignace Vergote, David Cibula, et al. · International Journal of Gynecological Cancer · 30
PDF
Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer
2021 · A.K. Nurgalieva, V.E. Popov, et al. · Biochemistry and Biophysics Reports · 22
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
2021 · Salma K. Jabbour, Ki Hyeong Lee, et al. · Journal of Clinical Oncology · 18
Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
2020 · Ilya Tsimafeyeu, Oxana Shatkovskaya, et al. · Cancer Reports · 13
PDF
Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection
2020 · Ilya Tsimafeyeu, Rustem Gafanov, et al. · Cancer Immunology Immunotherapy · 12
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
2026 · Lisa Licitra, Makoto Tahara, et al. · Journal of Clinical Oncology · 11
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T
2014 · Ilya Tsimafeyeu, Anton Snegovoy, et al. · Targeted Oncology · 10
Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
2020 · Nancy Y. Lee, Ravindra Uppaluri, et al. · Cancer Research · 9
KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)
2023 · Arkadiy Klochikhin, Robert I. Haddad, et al. · European Journal of Surgical Oncology · 8
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
2024 · Ilya Tsimafeyeu, Vyacheslav Chubenko, et al. · Current Oncology · 6
PDF
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.
2024 · Martin Reck, Ki Hyeong Lee, et al. · Journal of Clinical Oncology · 6
Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
2020 · E. V. Borodavina, P. A. Isaev, et al. · Head and neck tumors (HNT) · 6
PDF
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
2019 · E. Cohen, R. Uppaluri, et al. · Annals of Oncology · 6
Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study
2019 · I. V. Tsimafeyeu, I. S. Varlamov, et al. · Malignant tumours · 6
PDF
Works count: 70
Citation count: 1,905
H-index: 15
I10-index: 19
Year
Topic
Type